| Part B: Supplementary Information Sheet (SIS) |
|
FR Recognition List Number
|
043
|
Date of Entry 06/27/2016
|
|
FR Recognition Number
|
3-143
|
| Standard | |
| ISO 12417 First edition 2015-10-01 Cardiovascular implants and extracorporeal systems - Vascular device-drug combination products |
|
Scope/Abstract| ISO 12417-1:2015 specifies requirements for vascular device-drug combination products (VDDCPs) based upon current technical and medical knowledge. VDDCPs are medical devices with various clinical indications for use in the human vascular blood system. A VDDCP incorporates, as an integral part, substance(s) which, if used separately, can be considered to be a medicinal substance or product (drug substance, drug product) but the action of the medicinal substance is ancillary to that of the device and supports the primary mode of action (PMOA) of the device. With regard to safety, this part of ISO 12417 outlines requirements for intended performance, design attributes, materials, design evaluation, manufacturing, sterilization, packaging, and information supplied by the manufacturer. For implanted products, this International Standard should be considered as a supplement to ISO 14630, which specifies general requirements for the performance of non-active surgical implants. This International Standard should also be considered as a supplement to relevant device-specific standards, such as the ISO 25539‑series specifying requirements for endovascular devices. Requirements listed in this part of ISO 12417 also address VDDCPs that are not permanent implants. |
|
Extent of Recognition
| Partial recognition. The following part(s) of the standard is (are) not recognized |
Clause 1.0, 2nd paragraph after the note: Exclude the following phrases "whose PMOA is; and, (e.g. infusion catheters), unless they contain a drug component that is intended to have an ancillary action to the device part (e.g. antimicrobial coated infusion catheter)."
Clause 4.3 Intended clinical location, h) intracerebral. |
|
Public Law, CFR Citation(s) and Procode(s)*
|
| Regulation Number |
Device Name |
Device Class |
Product Code |
| Unclassified |
Coronary Drug-Eluting Stent |
Class 3 |
NIQ |
|
| Regulation Number |
Device Name |
Device Class |
Product Code |
| Unclassified |
Drug Eluting Permanent Left Ventricular (Lv) Pacemaker Electrode |
Class 3 |
OJX |
| Unclassified |
Drug Eluting Permanent Right Ventricular (Rv) Or Right Atrial (Ra) Pacemaker Electrodes |
Class 3 |
NVN |
| Unclassified |
Drug-Eluting Peripheral Transluminal Angioplasty Catheter |
Class 3 |
ONU |
| Unclassified |
Permanent Defibrillator Electrodes |
Class 3 |
NVY |
| Unclassified |
Stent, Superficial Femoral Artery, Drug-Eluting |
Class 3 |
NIU |
|
Relevant FDA Guidance and/or Supportive Publications*
Draft Guidance for Industry: Coronary Drug-Eluting Stents - Nonclinical and Clinical Studies, Issued March 2008.
Draft Guidance for Industry: Coronary Drug-Eluting Stents - Nonclinical and Clinical Studies Companion Document , March 2008
Guidance for Industry and FDA Staff: General Considerations for Animal Studies for Cardiovascular Devices, July 29, 2010 |
|
| FDA Technical Contacts
|
| Standards Development Organization
|
| FDA Specialty Task Group (STG)
|
|
|
| *These are provided as examples and others may be applicable. |
